2025-05-15 - Analysis Report
Okay, here's a comprehensive report analyzing Johnson & Johnson (JNJ) based on the provided data.

## Johnson & Johnson (JNJ) Stock Analysis

**0. Introduction**

This report provides an analysis of Johnson & Johnson (JNJ) stock, comparing its performance against the S&P 500 (VOO), examining recent stock price movements, technical indicators, recent news, and financial information.

**1. Performance vs. S&P 500 (VOO)**

*   **Company Overview:** Johnson & Johnson is a multinational corporation that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **JNJ Cumulative Return:** 0.0
*   **VOO Cumulative Return:** 0.0
*   **Disparity:**
    *   **Max:** 0.0
    *   **Min:** 0.0
    *   **Current:** 0.0
    *   **Relative Disparity:** 0.0

*   **Alpha, Beta Analysis:**

    | Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
    |------------|-------|-------|-------|------|--------|
    | 2015-2017  | 0.0%  | 0.0%  | 0.0   | 1.0  | 274.9  |
    | 2016-2018  | 0.0%  | 0.0%  | 0.0   | 1.0  | 260.8  |
    | 2017-2019  | 0.0%  | 0.0%  | 0.0   | 1.0  | 303.1  |
    | 2018-2020  | 0.0%  | 0.0%  | 0.0   | 1.0  | 335.9  |
    | 2019-2021  | 0.0%  | 0.0%  | 0.0   | 1.0  | 374.3  |
    | 2020-2022  | 0.0%  | 0.0%  | 0.0   | 1.0  | 396.7  |
    | 2021-2023  | 0.0%  | 0.0%  | 0.0   | 1.0  | 362.7  |
    | 2022-2024  | 0.0%  | 0.0%  | 0.0   | 1.0  | 345.2  |
    | 2023-2025  | 0.0%  | 0.0%  | 0.0   | 1.0  | 352.1  |

    **Analysis:**
    *   **CAGR & MDD:** CAGR and MDD values are currently 0.0%, showing no change over time. This data needs to be checked for accuracy, as it does not reflect any growth or risk.
    *   **Alpha:** Alpha is consistently at 0.0, indicating that JNJ has not outperformed the market (S&P 500) during these periods.
    *   **Beta:** Beta is consistently 1.0, implying that JNJ's volatility is the same as the market.
    *   **Cap(B):** Market capitalization fluctuates between approximately $260B and $396B, showing significant scale and variability.

**2. Recent Stock Price Movement**

*   **Current Price:** 146.3487
*   **Last Market Data:**
    *   **Price:** 146.32
    *   **Previous Close:** 148.44
    *   **Change:** -1.43
*   **Moving Averages:**
    *   **5-day MA:** 153.5337
    *   **20-day MA:** 154.9924
    *   **60-day MA:** 158.8733

    **Analysis:**
    *   The current price is below all three moving averages (5-day, 20-day, and 60-day), suggesting a downward trend in the short to medium term.
    *   The recent change of -1.43 suggests a significant recent drop, potentially indicating a short-term negative sentiment.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.0 (Ranges: 0.45~0.35: Low Risk, 0.4~0.3: Medium Risk, 0.5~0.65: High Risk)
*   **RSI:** 28.968868586288977
*   **PPO:** -0.2937
*   **Recent (20-day) Relative Disparity Change:** 0.0 (-) - short-term decline
*   **Expected Return (%):** 0.0 - Long-term (2+ years) expected excess return compared to S&P 500

    **Analysis:**
    *   **MRI:** An MRI of 0.0 is outside the provided risk ranges, suggesting that the data is missing or incomplete. This should be investigated.
    *   **RSI:** An RSI of 28.97 indicates that the stock is nearing oversold territory (typically below 30), which *could* suggest a potential for a price rebound, but it doesn't *guarantee* it.
    *   **PPO:** A PPO of -0.2937 suggests the stock's short-term moving average is below its long-term moving average, confirming the downward trend indicated by the price being below all moving averages.
    *   **Recent Relative Disparity Change:** The short-term decline reinforces the negative trend.
    *   **Last-market Change Impact:** The significant negative change (-1.43) highlights a recent negative event influencing the stock.
    *   **Expected Return:** An expected return of 0.0% suggests that JNJ is not expected to outperform the S&P 500 over the long term at the current time.

**4. Recent News & Significant Events**

*   **[2025-05-14]:** Johnson & Johnson (JNJ) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **[2025-05-15]:** Analysts are discussing Johnson & Johnson's (JNJ) recent performance and its outlook in the context of industry trends and global economic factors.
*   **[2025-05-11]:** Johnson & Johnson (JNJ)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **[2025-05-13]:** Market experts highlight both risks and opportunities for Johnson & Johnson (JNJ), advising investors to monitor recent news and company announcements.

    **Analysis:**
    *   The recent news indicates that JNJ has been subject to business developments, regulatory changes, or market events. Analyst discussions and identified volatility suggests the need for investors to stay informed and monitor developments.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-04-23 | 4.57 | 21.89 B$  |
| 2024-10-23 | 1.12 | 22.47 B$  |
| 2024-07-25 | 1.95 | 22.45 B$  |
| 2024-05-01 | 1.35 | 21.38 B$  |
| 2025-04-23 | 1.35 | 21.38 B$  |

    **Analysis:**
    *   EPS fluctuated significantly over the past few quarters, with a high of 4.57 in 2025-04-23 and a low of 1.12 in 2024-10-23.
    *   Revenue has been relatively stable, ranging from 21.38 B$ to 22.47 B$.
    *  The duplicate date "2025-04-23" is shown, and the EPS of the last day is significantly lower than the previous. This needs to be verified.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-03-31 | $21.89B    | 66.40%        |
| 2024-12-31 | $22.52B    | 68.35%        |
| 2024-09-30 | $22.47B    | 69.01%        |
| 2024-06-30 | $22.45B    | 69.40%        |
| 2024-03-31 | $21.38B    | 69.55%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE   |
|------------|------------|-------|
| 2025-03-31 | $78.11B    | 14.08% |
| 2024-12-31 | $71.49B    | 4.80%  |
| 2024-09-30 | $70.16B    | 3.84%  |
| 2024-06-30 | $71.54B    | 6.55%  |
| 2024-03-31 | $70.02B    | 4.65%  |

    **Analysis:**

    *   **Revenue and Profitability:**
        *   Revenue has been relatively consistent around $22 billion per quarter, with a slight dip in the most recent quarter.
        *   Profit margins are high but have decreased from 69.55% to 66.40% in the most recent quarter. This could warrant further investigation to understand the underlying reasons for the decline.
    *   **Capital and Profitability:**
        *   Equity has generally increased over the period, indicating growth in the company's net assets.
        *   ROE (Return on Equity) shows significant variability, spiking to 14.08% in the most recent quarter after being consistently lower in previous quarters. This spike warrants scrutiny to determine if it's sustainable or due to one-time factors.

**7. Overall Analysis and Conclusion**

Based on the provided data, here is a summary:

*   **Performance:** Currently, JNJ's performance relative to the S&P 500 is neutral, with no difference in cumulative returns. However, the Alpha and Beta analysis shows it closely follows the market with no outperformance historically.
*   **Technicals:** The stock is currently in a short-term downward trend, as indicated by its price being below its moving averages and recent price drop. The RSI nearing oversold territory *might* suggest a potential rebound, but further confirmation is needed. The MRI value is missing or incorrect.
*   **News:** Recent news indicates that JNJ has been subject to business developments, regulatory changes, or market events.
*   **Earnings:** EPS and Revenue have shown some fluctuations.
*   **Financials:** Revenue has been stable. Profit margins have recently declined. Equity is growing, and ROE has recently spiked, potentially requiring further investigation to assess its sustainability.

**Overall Recommendation:**

A cautious approach is warranted. The stock is showing a short-term negative trend. However, recent news, volatility indicates that investors need to closely monitor the stock. The company's financials show relatively stable revenue, but declining profit margins and spiking ROE in the last quarter need further investigation. The data inconsistencies (CAGR, MDD, MRI, duplicate date in earning analysis) need to be verified before making a decision.
